Submitted by kBLASTER Team on
by PR Newswire
Bone Index Ltd., one of Europe's top new manufacturers of medical devices, has received 510(k) clearance from the Food and Drug Administration (FDA) for the Bindex® point-of-care instrument to help in osteoporosis diagnosis.
Osteoporosis, a very underdiagnosed disease, is responsible for two million broken bones every year in the USA. These fractures translate into costs totaling about 19 billion dollars. Experts forecast that by 2025, the costs due to fractures will rise to 25.3 billion dollars. Currently, one of the biggest challenges in osteoporosis management is the low availability of diagnostics since bone density scans are mostly performed in hospitals with large DXA X-ray machines that entail high costs.
Bindex® measures the cortical bone thickness of the tibia and the algorithm calculates the Density Index, a parameter which estimates bone mineral density at the hip as measured with DXA. Bindex detects osteoporosis with 90% sensitivity and specificity and will significantly help physicians with diagnosis.
"The clearance process with the FDA was straightforward despite the novel approach introduced with Bindex. The technique is based on extensive clinical evidence, and with the effectiveness of Bindex, the current care of osteoporosis can be significantly improved," said Bone Index's CTO, Dr. Janne Karjalainen.
Leverage kBLASTER's result management features of sorting, My Favorites, Saved Search and Search History to find a primary predicate, multiple predicates or reference devices. Build a 510(k) clearance strategy by enabling self-service extraction of actionable insight from nearly 64,000 FDA medical device 510(k) clearance summaries, plus more than 76,000 splash pages, for a total of more than 140,000 records.